In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic rhinosinusitis (CRS) nasal spray Xhance for up to $330 million. Triggering the ...

XHANCE. The nasal spray, designed to treat chronic rhinosinusitis without nasal polyps, recorded net revenues of $14.9 million, marking a 26% increase from the first quarter of 2023. The company ...

XHANCE is an innovative, drug-device combination product approved for the treatment of CRS with or without nasal polyps. By optimally targeting the site of inflammation with a proven ...

Xhance is an innovative drug-device therapy for chronic rhinosinusitis (CRS), with or without nasal polyps. Utilizing its proprietary Exhalation Delivery System, it delivers a corticosteroid ...